S1296
Clinical - Urology
ESTRO 2026
Mini-Oral 4350
trial of definitive carbon-ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks. Br J Cancer. 2014;110(10):2389-2395. doi:10.1038/bjc.2014.191.2. Sato H, Shioyama Y, Ogawa Y, Okamoto Y, Terashima K, Saitoh J-I, Kasuya G, Nomiya T, Tsuji H, Kamada T.Long-term clinical outcomes after 12-fractionated carbon-ion radiotherapy for localized prostate cancer. Cancer Sci. 2021;112(4):1659-1667. doi:10.1111/cas.15019. Keywords: CIRT, Prostate cancer, Dose escalation Extreme hypofractionation is less lympho-toxic than moderate hypofractionaton after post- prostatectomy salvage radiotherapy Marta Bottero 1 , Adriana Faiella 1 , Alessia Farneti 1 , Luca Tagliaferri 2 , Pierpaolo Dragonetti 2 , Alessandro Magli 3 , Enrico Raggi 3 , Elisa Villa 4 , Riccardo Mazzola 5 , Emanuele Alì 6 , Federico Iori 6 , Giuseppe Sanguineti 1 1 Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy. 2 Radiation Oncology, Gemelli ART (Advanced Radiation Therapy), Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS, Rome, Italy. 3 Radiation Oncology, ASUGI, Trieste, Italy. 4 Radiation Oncology, Humanitas Gavazzeni, Bergamo, Italy. 5 Radiation Oncology, Humanitas, Bergamo, Italy. 6 Radiation Oncology, Azienda USL-IRCCS, Reggio Emilia, Italy Digital Poster Highlight 4346
Long-Term Follow Up of the HypoFocal Phase II Trial: PSMA-PET- /MRI-based Focal Dose Escalated Radiotherapy for Intermediate/High-Risk Prostate Cancer Simon KB Spohn 1,2 , Constantinos Zamboglou 1,3 , Sophia L Bürkle 1,4 , Martin T Freitag 5 , Joachim Brumberg 5 , Hannes Engel 6 , Mark Gainey 7,2 , Marius Kamps 8 , Paolina Toncheva 1,2 , Tanja Sprave 1,2 , Simon Kirste 1,9 , August Sigle 8 , Cordula A Jilg 8 , Christian Gratzke 8 , Sonja Adebahr 1 , Michael Mix 5 , Fabian Bamberg 6 , Sebastian Zschaeck 10,11 , Pirus Ghadjar 10 , Dimos Baltas 7,2 , Anca L Grosu 1,2 1 Department of Radiation Oncology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany. 2 German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany. 3 German Oncology Center, European University of Cyprus, Limassol, Cyprus. 4 German Cancer Consortium (DKTK), Partner Site Freiburg, Frei, Germany. 5 Department of Nuclear Medicine, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany. 6 Department of Radiology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany. 7 Department of Radiation Oncology - Division of Medical Physics, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany. 8 Department of Urology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany. 9 German Cancer Consortium (DKTK), Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany. 10 Department of Radiation Oncology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Berlin, Germany. 11 German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany Purpose/Objective: Hypofractionation and focal dose escalation in primary prostate cancer (PCa) enable reduction of treatment time and isotoxic treatment improvement. The HypoFocal phase II trial investiagtes focal dose escalated radiotherapy based on multiparametric- magentic-resonance-tomography (mpMRI) and positron-emission-tomography targeting prostate- specific-membrane-antigen (PSMA-PET). Here we present toxicity and treatment outcomes of the HypoFocal Phase II trial after a median follow up (FU) of > 48 months. Material/Methods: Intermediate- and high-risk PCa patients were treated with moderately hypofractionated radiotherapy (MHRT) of 60Gy in 20 fractions and a focal-boost of up to 75Gy in Arm A, or high-dose-rate-brachytherapy (HDR-BT) of 15Gy to the whole-gland with a boost of
Made with FlippingBook - Share PDF online